Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving viable micro-organism
Reexamination Certificate
2006-03-21
2006-03-21
McKelvey, Terry (Department: 1636)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving viable micro-organism
C435S035000
Reexamination Certificate
active
07015012
ABSTRACT:
The present invention is based, in part, on the discovery of methods for identifying compounds that mediate (by promoting or inhibiting) protein-protein interaction (e.g., aggregation, dimerization, or other physiologically significant association). Compounds that mediate such interaction, which are also within the scope of the invention, can be used to treat Alzheimer's disease, disorders associated with expanded CAG repeats (such as Huntington's disease), and disorders in which polyglutamine-containing transcription factors or coactivators are undesirably active (e.g., disorders associated with homodimerization of jun or hexamerization of p53.
REFERENCES:
patent: 5144011 (1992-09-01), Shen et al.
patent: 5328470 (1994-07-01), Nabel
patent: 5849995 (1998-12-01), Hayden
patent: 5994392 (1999-11-01), Shashoua
patent: 6015555 (2000-01-01), Friden
patent: 6177259 (2001-01-01), Yuan
patent: 6355690 (2002-03-01), Tsuji
patent: WO 01/23412 (2001-04-01), None
Ambrose et al., “Structure and Expression of the Huntington's Disease Gene: Evidence against Simple Inactivation Due to an Expanded CAG Repeat,”Somat. Cell Mol. Genet.20:27-38 (1994).
Bates et al., “Transgenic Mice in the Study of Polyglutamine Repeat Expansion Diseases,”Brain Pathol.8:699-714 (1998).
Burright et al., “SCAI Transgenic Mice: A Model for Neurodegeneration Caused by an Expanded CAG Trinucleotide Repeat,”Cell82:937-948 (1995).
Chen et al., “Gene Therapy for Brain Tumors: Regression of Experimental Gliomas by Adenovirus-Mediated Gene TransferIn Vivo,”Proc. Natl. Acad. Sci. USA91:3054-3057 (1994).
Chicurel et al., “Expression of Huntington's Disease Mutation in Mice,” at http://www.hdfoundation.org/PDF/hdmicetable.pdf (2000).
Cruikshank et al., “A Lipidated Anti-Tat Antibody Enters Living Cells and Blocks HIV-1 Viral Replication,”J. Acquired Immune Deficiency Syndromes and Human Retrovirology14:193-203 (1997).
Davies et al., “Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation,”Cell90:537-548 (1997).
DiFiglia et al., “Aggregration of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain,”Science277:1990-1993 (1997).
Duyao et al., “Inactivation of the Mouse Huntington's Disease Gene HomologHdh,”Science269:407-410 (1995).
Gatter et al., “Transferrin Receptors in Human Tissues: Their Distribution and Possible Clinical Relevance,”J. Clin. Path.36:539-545 (1983).
Gavilondo-Cowley et al., “Specific Amplification of Rearranged Immunoglobulin Variable Region Genes from Mouse Hybridoma Cells,”Hybridoma9:407-417 (1990).
Goldstein et al., “Science and the Citizen,”Scientific American255:74-91 (1996).
Gutekunst et al., “Nuclear and Neuropil Aggregates in Huntinton's Disease: Relationship to Neuropathology,”J. Neurosci.19:2522-2534 (1999).
Haynes et al., “Characterization of a Monoclonal Antibody (5E9) that Defines a Human Cell Surface Antigen of a Cell,”J. Immunol.127:347-351 (1981).
Hodgson et al., “A YAC Mouse Model for Huntington's Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration,”Neuron23:181-192 (1999).
Hogan et al.,Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1994).
Ikeda et al., “Expanded Polyglutamine in the Machado-Joseph Disease Protein Induces Cell DeathIn VitroandIn Vivo, ”Nature Genet.13:196-202 (1996).
Kakizuka, “Protein Precipitation: A Common Etiology in Neurodegenerative Disorders?,”Trends Genet.14:396-402 (1998).
Kazantsev et al., “Insoluble Detergent-Resistant Aggregates Form Between Pathological and Nonpathological Lengths of Polyglutamine in Mammalian Cells,”Proc. Natl. Acad. Sci. USA96:11404-11409 (1999).
Klement et al., “Ataxin-1 Nuclear Localization and Aggregation: Role in Polyglutamine-Induced Disease inSCAITransgenic Mice,”Cell95:41-53 (1998).
Larrick et al., “Polymerase Chain Reaction Using Mixed Primers: Cloning of Human Monoclonal Antibody Variable Region Genes from Single Hybridoma Cells,”Bio/technology7:934-938 (1989).
Lebman et al., “A Monoclonal Antibody that Detects Expression of Transferrin Receptor in Human Erythroid Precursor Cells,”Blood59:671-678 (1982).
Li et al., “Ultrastructural Localization and Progressive Formation of Neuropil Aggregates in Huntington's Disease Transgenic Mice,”Hum. Mol. Getter.8:1227-1236 (1999).
Mangiarini et al., “Exon 1 of the HD Gene with an Expanded CAG Repeat is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice,”Cell87:493-506 (1996).
Omary et al., “Human Cell-Surface Glycoprotein with Unusual Properties,”Nature286:888-891 (1980).
Onodera et al., “Oligomerization of Expanded Polyglutamine Domain Fluorescent Fusion Proteins in Cultured Mammalian Cells,”Biochemical and Biophysical Research Communications, 238:599-605 (1977).
Orlandi et al., “Cloning Immunoglobulin Variable Domains for Expression by the Polymerase Chain Reaction,”Proc. Nat. Acad. Sci. USA86:3833-3837 (1989).
Pardridge et al., “Receptor-Mediated Peptide Transport through the Blood-Brain Barrier,”Endocrin. Rev.7:314-330 (1986).
Paulson et al., “Protein Fate in Neurodegenerative Proteinopathies: Polyglutamine Diseases Join the (Mis)Fold,”Am. J. Hum. Genet.64:339-345 (1999).
Perutz et al., “Glutamine Repeats and Neurodegenerative Diseases: Molecular Aspects,”Trends Biochem. Sci.24:58-63 (1999).
Reddy et al., “Recent Advances in Understanding the Pathogenesis of Huntington's Disease,”Trends Neuroscience22:248-255 (1999).
Ross et al., “Intranuclear Neuronal Inclusions: A Common Pathogenic Mechanism for Glutamine-Repeat Neurodegenerative Diseases,”Neuron19:1147-1150 (1997).
Saudou et al., “Huntingtin Acts in the Nucleus to Induce Apoptosis but Death Does Not Correlate with the Formation of Intranuclear Inclusions,”Cell95:55-66 (1998).
Scherzinger et al., “Self-Assembly of Polyglutamine-Containing untingtin Fragments into Amyloid-Like Fibrils: Implications for Huntington's Disease Pathology,”Proc. Natl. Acad. Sci. USA96;4604-4609 (1999).
Sutherland et al., “Ubiquitous Cell-Surface Glycoprotein on Tumor Cells is Proliferation-Associated Receptor for Transferrin,”Proc. Natl. Acad. Sci. USA78:4515-4519 (1981).
Zeitlin et al., “Increased Apoptosis and Early Embryonic Lethality in Mice Nullizygous for the Huntington's Disease Gene Homologue,”Nature Genet.11:155-163 (1995).
Zhuchenko et al., “Autosomal Dominant Cerebellar Ataxia (SCA6) Associated with Small Polyglutamine Expansions in the - Voltage-Dependent Calcium Channel,”Nature15:62-69 (1997).
Housman David E.
Kazantsev Aleksey G.
Fish & Richardson P.C.
Massachusetts Institute of Technology
McKelvey Terry
LandOfFree
Methods of identifying agents that mediate polypeptide... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of identifying agents that mediate polypeptide..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of identifying agents that mediate polypeptide... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3597371